Stewart SH, et al. - Researchers sought to determine how combined outpatient naltrexone (NTX) treatment with Alcoholics Anonymous Facilitation (AAF) behavior therapy is beneficial, in the context of OPRM1 genotype. Given an association of minor OPRM1 Asp40 G-allele with greater positive reinforcing effects of alcohol consumption and greater alcohol craving, an improved naltrexone response is possible among individuals carrying the OPRM1G allele. Ninety days of naltrexone with medication support and dispensing sessions and ten AAF behavior therapy sessions were provided to 20 patients, including 7 G-allele carriers. The sample as a whole displayed an overall increase in percent days abstinent during treatment and the 8-week posttreatment follow-up, however, G-allele carriers reported relatively heavier drinking relative to other individuals. Findings thereby indicate the promising therapeutic value of this enhanced medication-assisted behavior treatment and mirror other recent findings that G-allele carriers may require more intensive treatment.